96 related articles for article (PubMed ID: 17115102)
1. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment.
Wiseman SM; Masoudi H; Niblock P; Turbin D; Rajput A; Hay J; Bugis S; Filipenko D; Huntsman D; Gilks B
Ann Surg Oncol; 2007 Feb; 14(2):719-29. PubMed ID: 17115102
[TBL] [Abstract][Full Text] [Related]
2. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma.
Wiseman SM; Masoudi H; Niblock P; Turbin D; Rajput A; Hay J; Filipenko D; Huntsman D; Gilks B
Am J Surg; 2006 May; 191(5):581-7. PubMed ID: 16647341
[TBL] [Abstract][Full Text] [Related]
3. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
Elliott DD; Sherman SI; Busaidy NL; Williams MD; Santarpia L; Clayman GL; El-Naggar AK
Hum Pathol; 2008 Jan; 39(1):15-20. PubMed ID: 17949783
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.
Montero-Conde C; Martín-Campos JM; Lerma E; Gimenez G; Martínez-Guitarte JL; Combalía N; Montaner D; Matías-Guiu X; Dopazo J; de Leiva A; Robledo M; Mauricio D
Oncogene; 2008 Mar; 27(11):1554-61. PubMed ID: 17873908
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma.
Wiseman SM; Griffith OL; Gown A; Walker B; Jones SJ
Am J Surg; 2011 May; 201(5):580-6. PubMed ID: 21545903
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 expression in primary thyroid carcinomas.
Sporny S; Slowinska-Klencka D; Ratynska M
Neuro Endocrinol Lett; 2005 Dec; 26(6):815-8. PubMed ID: 16380680
[TBL] [Abstract][Full Text] [Related]
7. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma.
Weinberger PM; Adam BL; Gourin CG; Moretz WH; Bollag RJ; Wang BY; Liu Z; Lee JR; Terris DJ
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):503-10. PubMed ID: 17515507
[TBL] [Abstract][Full Text] [Related]
8. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma.
Lee SH; Lee JK; Jin SM; Lee KC; Sohn JH; Chae SW; Kim DH
Otolaryngol Head Neck Surg; 2010 Mar; 142(3):332-7. PubMed ID: 20172376
[TBL] [Abstract][Full Text] [Related]
9. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy.
Wiseman SM; Loree TR; Rigual NR; Hicks WL; Douglas WG; Anderson GR; Stoler DL
Head Neck; 2003 Aug; 25(8):662-70. PubMed ID: 12884350
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas.
Pallante P; Visone R; Croce CM; Fusco A
Endocr Relat Cancer; 2010 Mar; 17(1):F91-104. PubMed ID: 19942715
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles in thyroid carcinomas.
Takano T; Hasegawa Y; Matsuzuka F; Miyauchi A; Yoshida H; Higashiyama T; Kuma K; Amino N
Br J Cancer; 2000 Dec; 83(11):1495-502. PubMed ID: 11076659
[TBL] [Abstract][Full Text] [Related]
14. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.
Garcia-Rostan G; Tallini G; Herrero A; D'Aquila TG; Carcangiu ML; Rimm DL
Cancer Res; 1999 Apr; 59(8):1811-5. PubMed ID: 10213482
[TBL] [Abstract][Full Text] [Related]
15. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas.
Motti ML; Califano D; Baldassarre G; Celetti A; Merolla F; Forzati F; Napolitano M; Tavernise B; Fusco A; Viglietto G
Carcinogenesis; 2005 Jun; 26(6):1021-34. PubMed ID: 15718252
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer.
Chakravarty G; Santillan AA; Galer C; Adams HP; El-Naggar AK; Jasser SA; Mohsin S; Mondal D; Clayman GL; Myers JN
Exp Biol Med (Maywood); 2009 Apr; 234(4):372-86. PubMed ID: 19176870
[TBL] [Abstract][Full Text] [Related]
17. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
18. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.
Klopper JP; Berenz A; Hays WR; Sharma V; Pugazhenthi U; Janssen J; Singh M; Bissonnette RP; Haugen BR
Clin Cancer Res; 2008 Jan; 14(2):589-96. PubMed ID: 18223235
[TBL] [Abstract][Full Text] [Related]
19. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein e expression in anaplastic thyroid carcinoma.
Ito Y; Takano T; Miyauchi A
Oncology; 2006; 71(5-6):388-93. PubMed ID: 17690558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
